Back >>

Does NIH recommend remdesivir in mild to moderate cases of COVID-19?

Comment by InpharmD Researcher

The NIH makes no official recommendations for the use of remdesivir in COVID-19 patients. Their sponsored trials observing remdesivir included hospitalized COVID-19 patients with evidence of lung infiltration or need for oxygen supplementation.
Background

According to the National Institute of Health (NIH) management guidelines for COVID-19, no drug has yet to be proven as safe and effective for COVID-19 treatment. Remdesivir is currently under investigation and is not yet recommended by the NIH. [1-2]

The two NIH-funded clinical trials, the Adaptive COVID-19 Treatment Trial (observing remdesivir alone) and the ACTT 2 trial (observing remdesivir plus baricitinib) are both used in hospitalized patients with evidence of lung involvement or need for oxygen supplementation. [2-4]

References:

[1] National Institute of Health (NIH). Management of Persons with COVID-19. Available: https://covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/. Updated: April 21, 2020. Accessed May 19, 2020.
[2] National Institute of Health (NIH). NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. Available: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. Published: April 29, 2020. Accessed May 19, 2020.
[3] National Institute of Health (NIH). NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins. Available: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-antiviral-remdesivir-plus-anti-inflammatory-drug-baricitinib-covid-19-begins. Published May 8, 2020. Accessed May 19, 2020.
[4] Clinicaltrials.gov. Adaptive COVID-19 Treatment Trial (ACTT). Available: https://clinicaltrials.gov/ct2/show/NCT04280705. Updated: May 7, 2020. Accessed May 19, 2020.